Sagent Pharmaceuticals (SGNT) Misses Q4 EPS Views; Guides FY16 Revenue Below Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results
February 16, 2016 7:30 AM ESTEstablishes Long-Term Growth Strategy to Expand Product Offerings, Enhance Operational Performance, and Execute on Strategic Acquisitions
Enters Into Agreement to Sell Sagent (China) Pharmaceuticals (SCP) Reducing Cost Structure by Approximately $10 Million Per Year
Affirms Full Year Guidance Including Revenue and Adjusted EBITDA Growth Expectations for 2016
SCHAUMBURG, Ill., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced financial results for the fourth quarter and fiscal year ended December... More
